These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 923106

  • 1. Evidence for a dopaminergic activity of methysergide in humans.
    Oppizzi G, Verde G, De Stefano L, Cozzi R, Botalla L, Liuzzi A, Chiodini PG.
    Clin Endocrinol (Oxf); 1977 Oct; 7(4):267-72. PubMed ID: 923106
    [Abstract] [Full Text] [Related]

  • 2. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.
    Ferrari C, Rampini P, Paracchi A, Boghen M, Mailland F.
    Eur J Clin Pharmacol; 1985 Oct; 27(6):707-11. PubMed ID: 3921384
    [Abstract] [Full Text] [Related]

  • 3. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.
    Camanni F, Massara F, Belforte L, Rosatello A, Molinatti GM.
    J Clin Endocrinol Metab; 1977 Mar; 44(3):465-73. PubMed ID: 838847
    [Abstract] [Full Text] [Related]

  • 4. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly.
    Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG, Birkenhäger JC.
    Eur J Clin Invest; 1982 Apr; 12(2):151-5. PubMed ID: 6807686
    [Abstract] [Full Text] [Related]

  • 5. No acute effect of pimozide on the plasma GH levels in acromegaly.
    Nortier JW, Croughs RJ, Donker GH, Thijssen JH, Schwarz F.
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
    [Abstract] [Full Text] [Related]

  • 6. Effect of bromoergocriptine on TRH-induced growth hormone and prolactin release in acromegalic patients.
    Ishibashi M, Yamaji T, Kosaka K.
    J Clin Endocrinol Metab; 1977 Aug; 45(2):275-9. PubMed ID: 407240
    [Abstract] [Full Text] [Related]

  • 7. Interaction between the thyrotrophin-releasing hormone-induced growth hormone rise and dopaminergic drugs: studies in pathologic conditions of the animal and man.
    Müller EE, Salerno F, Cocchi D, Locatelli V, Panerai AE.
    Clin Endocrinol (Oxf); 1979 Dec; 11(6):645-56. PubMed ID: 119594
    [Abstract] [Full Text] [Related]

  • 8. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin.
    Werner S, Hall K, Sjöberg HE.
    Acta Endocrinol Suppl (Copenh); 1978 Dec; 216():199-206. PubMed ID: 347862
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.
    Chiodini PG, Liuzzi A, Muller EE, Botalla L, Cremascoli G, Oppizzi G, Verde G, Silvestrini F.
    J Clin Endocrinol Metab; 1976 Aug; 43(2):356-63. PubMed ID: 950367
    [Abstract] [Full Text] [Related]

  • 10. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep.
    Clarenbach P, Del Pozo E, Brownell J, Heredia E, Spiegel R, Cramer H.
    Brain Res; 1980 Dec 08; 202(2):357-63. PubMed ID: 7437907
    [Abstract] [Full Text] [Related]

  • 11. A neuroendocrinological investigation of patients with senile demantia of Alzheimer type. Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.
    Fujita M, Shimizu T.
    Bull Osaka Med Sch; 1986 Oct 08; 32(2):73-84. PubMed ID: 3122863
    [No Abstract] [Full Text] [Related]

  • 12. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
    Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A.
    Clin Endocrinol (Oxf); 1988 Nov 08; 29(5):467-76. PubMed ID: 2908102
    [Abstract] [Full Text] [Related]

  • 13. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A.
    Acta Endocrinol (Copenh); 1983 Aug 08; 103(4):446-50. PubMed ID: 6310918
    [Abstract] [Full Text] [Related]

  • 14. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
    Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R.
    J Clin Endocrinol Metab; 1978 Feb 08; 46(2):196-202. PubMed ID: 108287
    [Abstract] [Full Text] [Related]

  • 15. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M, Yamaji T.
    J Clin Invest; 1984 Jan 08; 73(1):66-78. PubMed ID: 6140273
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interaction of dopaminergic and antiserotoninergic drugs in the control of prolactin and LH release in normal women.
    Pontiroli AE, Alberetto M, Pellicciotta G, De Castro e Silva E, De Pasqua A, Girardi AM, Pozza G.
    Acta Endocrinol (Copenh); 1980 Mar 08; 93(3):271-6. PubMed ID: 7376792
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Failure of naloxone to alter growth hormone and prolactin levels in acromegalic and in hyperprolactinaemic patients.
    Blankstein J, Reyes F, Winter J, Faiman C.
    Clin Endocrinol (Oxf); 1979 Nov 08; 11(5):475-9. PubMed ID: 391445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.